Nephrotoxicity of recent anti-cancer agents

被引：75
作者：
Lameire, Norbert [1 ]
机构：
[1] Univ Hosp, 185 Pintelaan, B-9000 Ghent, Belgium
来源：
CLINICAL KIDNEY JOURNAL | 2014年 / 7卷 / 01期
关键词：
anti-angiogenesis drugs and cancer; anti-cancer drugs and nephrotoxicity; androgen deprivation therapy and AKI;
D O I：
10.1093/ckj/sft135
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Cancer patients may develop a variety of kidney lesions that impair not only their immediate survival but also limit the adequate treatment of the underlying malignant process. This review summarizes the nephrotoxic potential of some of the most recently developed anti-cancer drugs, focusing on those interfering with the vascular endothelial growth factor and epidermal growth factor receptor pathways and mammalian target of rapamycin inhibitors. Thrombotic microangiopathy (haemolytic-uraemic syndrome), proteinuria, hypertension and magnesium depletion are the most common side effects. Also the risk for developing acute kidney injury in patients with advanced prostate cancer undergoing androgen deprivation therapy is discussed.
引用
收藏
页码：11 / 22
页数：12
相关论文
共 112 条
[1]   Ibrutinib and novel BTK inhibitors in clinical development [J].
Akinleye, Akintunde ;
Chen, Yamei ;
Mukhi, Nikhil ;
Song, Yongping ;
Liu, Delong .
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
[2]   Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review [J].
Al Ustwani, Omar ;
Lohr, James ;
Dy, Grace ;
Levea, Charles ;
Connolly, Gregory ;
Arora, Pradeep ;
Iyer, Renuka .
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2014, 5 (01) :E30-E33
[3]   Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention [J].
Albini, Adriana ;
Pennesi, Giuseppina ;
Donatelli, Francesco ;
Cammarota, Rosaria ;
De Flora, Silvio ;
Noonan, Douglas M. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (01) :14-25
[4]   Flutamide-induced acute renal failure in a patient with metastatic prostate cancer [J].
Altiparmak, MR ;
Bilici, A ;
Kisacik, B ;
Ozguroglu, M .
MEDICAL ONCOLOGY, 2002, 19 (02) :117-119
[5]   Estimation of Renal Function - What is Appropriate in Cancer Patients? [J].
Barraclough, L. H. ;
Field, C. ;
Wieringa, G. ;
Swindell, R. ;
Livsey, J. E. ;
Davidson, S. E. .
CLINICAL ONCOLOGY, 2008, 20 (10) :721-726
[6]   Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report [J].
Bharthuar, Anubha ;
Egloff, Lori ;
Becker, Joanne ;
George, Marina ;
Lohr, James W. ;
Deeb, George ;
Iyer, Renuka V. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (01) :177-181
[7]   Clinical course of haemodialysis patients with malignancies and dose-adjusted chemotherapy [J].
Boesler, B ;
Czock, D ;
Keller, F ;
Griesshammer, M ;
Seufferlein, T ;
Karges, W ;
Rasche, FM .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (06) :1187-1191
[8]   Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations [J].
Broxterman, HJ ;
Georgopapadakou, NH .
DRUG RESISTANCE UPDATES, 2005, 8 (04) :183-197
[9]   TSC2 regulates VEGF through mTOR-dependent and -independent pathways [J].
Brugarolas, JB ;
Vazquez, F ;
Reddy, A ;
Sellers, WR ;
Kaelin, WG .
CANCER CELL, 2003, 4 (02) :147-158
[10]   Meta-Analysis of Incidence and Risk of Hypomagnesemia with Cetuximab for Advanced Cancer [J].
Cao, Yunfei ;
Liao, Cun ;
Tan, Aihua ;
Liu, Lidan ;
Gao, Feng .
CHEMOTHERAPY, 2010, 56 (06) :459-465
12345678910